(Total Views: 594)
Posted On: 05/03/2022 9:46:00 PM
Post# of 148899
Re: Hyperbolic #122842
Did not see one. Here is the only paragraph discussing results that I left out:
Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, commented, “We wish to thank our entire NASH team led by Dr. Recknor, who has done a phenomenal job conducting this study. We are very excited about these results and the potential for helping the millions of individuals effected by NASH across the world. The main focus after seeking approval in the U.S. will be the UK, Canada, Brazil, and the Philippines. Hitting our primary endpoint in both ITT and per protocol (PP) and secondary endpoint in PP with such short trial (14-week trial as compared to usually 24 to 32-week NASH trials) is a very strong statement of leronlimab’s potential. We believe we have a unique drug with tremendous opportunities.”
You should be able to open the PR (PDF file) at this link.
https://web.archive.org/web/20220105143218/ht...et_592.pdf
Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, commented, “We wish to thank our entire NASH team led by Dr. Recknor, who has done a phenomenal job conducting this study. We are very excited about these results and the potential for helping the millions of individuals effected by NASH across the world. The main focus after seeking approval in the U.S. will be the UK, Canada, Brazil, and the Philippines. Hitting our primary endpoint in both ITT and per protocol (PP) and secondary endpoint in PP with such short trial (14-week trial as compared to usually 24 to 32-week NASH trials) is a very strong statement of leronlimab’s potential. We believe we have a unique drug with tremendous opportunities.”
You should be able to open the PR (PDF file) at this link.
https://web.archive.org/web/20220105143218/ht...et_592.pdf
(3)
(0)Scroll down for more posts ▼
